BioArctic rises as FDA clears Leqembi injection for maintenance use

BioArctic AB shares rose over 3% following the FDA's approval of Leqembi IQLIK, a subcutaneous version of its Alzheimer's drug, for maintenance treatment. This weekly injection offers an alternative to current intravenous infusions, potentially easing capacity constraints at infusion centers and reducing regulatory risk for future initial subcutaneous dosing, with a filing for the latter expected soon and potential approval by H1 2026.

Analysis

BioArctic AB shares responded positively, rising over 3%, to the U.S. Food and Drug Administration's approval of Leqembi IQLIK, a subcutaneous formulation of its Alzheimer's drug. This approval is specifically for maintenance treatment, offering a 360mg weekly injection as an alternative to monthly intravenous infusions for patients who have completed 18 months of initial IV therapy. According to an analyst note from RBC Capital Markets, the immediate impact of this new formulation, which is scheduled to launch in the U.S. on October 6, is its potential to alleviate capacity constraints at infusion centers. More strategically, this regulatory clearance is seen as a significant de-risking event for the company's pipeline. It strengthens the case for a future subcutaneous version for the initial treatment phase, for which a filing is expected soon with potential FDA approval anticipated in the first half of 2026. This validation of the subcutaneous delivery method is a critical milestone that could broaden the drug's future market access and patient convenience.

Key Decisions for Investors

• Investors should monitor the U.S. launch on October 6 and subsequent uptake data to gauge the new formulation's impact on alleviating infusion center capacity and its contribution to revenue.
• The primary long-term value driver is now the forthcoming regulatory filing and potential H1 2026 approval for the subcutaneous version for initial treatment; this maintenance approval significantly increases its probability of success.
• Given the positive regulatory development, it is prudent to reassess valuation models for BioArctic to factor in a potentially larger and more accessible market for the entire Leqembi franchise.